Skip to content
TerminatedNot applicableResults posted

Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects

NCT02669043 · Massachusetts General Hospital

Closed to entry
Status
Not accepting participants
Not applicable
Phase
8
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hours in many patients with "treatment-resistant" depression, has been associated with superior efficacy in those individuals with anxious compared with non-anxious depression. In order to understand this unique effect more fully, the current protocol is aimed at further delineating biomarkers of ketamine's effects among individuals with treatment-resistant anxious depression compared to those with nonanxious depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Hamilton Depression Rating Scale (HDRS, HAM-D)

    Measured over 48 hours

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. be 18-64 years old, 2. read, understand, and provide written informed consent in English, 3. meet criteria for a primary psychiatric diagnosis of Major Depressive Disorder (MDD) for ≥ 4 weeks, 4. have a history ≥1 failed medication trial during the current depression, 5. be on a stable adequate dose of an FDA-approved antidepressant medication for ≥28 days, 6. maintain a treating doctor who is in agreement with study participation, 7. have a reliable chaperone to accompany them home following the completion of the ketamine infusion day, 8. be generally healthy, as assessed by medical history, physical examination (including vital signs), clinical laboratory evaluations, and electrocardiogram (EKG), 9. be of non-childbearing potential or use of an acceptable form of birth control (females only). Exclusion Criteria: 1. delirium or dementia diagnosis, 2. unstable medical illness or clinically significant laboratory results, 3. history of clinically significant cardiovascular disease or electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for possible cardiac side effects (e.g., requirement of cardiac pacemaker) or alter brain morphology (e.g., recent head trauma, post intracranial surgery, intracranial mass or bleed or unstable sleep apnea), or a blood pressure \>140/95 mmHg at Screening, 4. history of multiple adverse drug reactions, 5. current/past history of psychotic disorders, history of out-of-body feelings or derealization, 6. active substance use disorders (except nicotine and caffeine) within the past six months or past history of ketamine/PCP (phencyclidine) abuse (we will confirm this with collateral information from their doctor if necessary), 7. requirement of excluded medications that may interact with ketamine, 8. caffeine or nicotine use within 1 hour of psychophysiology testing, or alcohol use within 1 day of testing, 9. pregnancy, breastfeeding, or unacceptable means of birth control (females only) 10. clinically significant hearing impairment, 11. current serious suicidal or homicidal risk, 12. concurrent participation in other research studies involving medications or other treatments, 13. narrow angle glaucoma, 14. acute intermittent porphyria history, 15. history of seizures in the past 6 months, regardless of seizure type, 16. hyperthyroidism or untreated hypothyroidism, 17. airway instability or pulmonary disease with hypercarbia, or 18. current or past cubital or carpal tunnel syndrome.

Where

1 study site

FacilityCityRegionCountry
Massachusetts General HospitalBostonMassachusettsUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02669043 on ClinicalTrials.gov →

Last updated in the registry 2018-04-23. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits